CM
RYTM icon

Crestline Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Crestline Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,062
Closed -$1.4M – 524
2024
Q4 		$1.4M Buy
25,062
+6,064
+32% +$335K 0.05% 353
2024
Q3 		$995K Buy
+18,998
New +$910K 0.05% 276
2018
Q3 		– Sell
-41,047
Closed -$1.28M – 222
2018
Q2 		$1.28M Buy
+41,047
New +$1.12M 0.13% 177

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Crestline Management's RYTM Position: Q1 2025 in Review

Crestline Management sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2025, closing a stake of 25,062 shares — an estimated $1.4M sold.

Crestline Management first reported a position in RYTM in Q2 2018 and held it in 3 quarters. The position peaked at $1.4M in Q4 2024. 228 funds tracked by Wall St. Rank hold RYTM as of Q1 2025.

  • Crestline Management reported no remaining Rhythm Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 25,062 Rhythm Pharmaceuticals shares in Q1 2025, an estimated $1.4M.
  • Crestline Management first reported a position in Rhythm Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Crestline Management's Rhythm Pharmaceuticals position peaked at $1.4M in Q4 2024.
  • 228 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.